Company Website:
http://www.faruqilaw.com/
NEW YORK -- (Business Wire)
Faruqi & Faruqi, LLP, a leading national securities law firm, is
investigating potential claims against Acorda Therapeutics, Inc.
(“Acorda” or the “Company”) (NASDAQ:ACOR).
Specifically, on November 15, 2017, Acorda announced that it had
identified seven cases of sepsis in patients, five of which were fatal,
during the final-stage trial studies of the Company’s treatment for
Parkinson’s disease, tozadenant. The Company also announced that new
patient enrollment in the trial would be stopped.
On this news, Acorda’s share price significantly declined.
If you invested in Acorda stock or options and would like to
discuss your legal rights, click here:www.faruqilaw.com/ACOR.
There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll freeat
877-247-4292 or at 212-983-9330 or by sending an e-mail torgonnello@faruqilaw.com.
Attorney Advertising. The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter. We welcome the opportunity to discuss your
particular case. All communications will be treated in a confidential
manner.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171120005702/en/
Contacts:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New
York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone:
(877) 247-4292 or (212) 983-9330
Source: Faruqi & Faruqi, LLP
© 2024 Canjex Publishing Ltd. All rights reserved.